Johns Hopkins University researchers who used PET found that the rate of rifampin penetration to tuberculosis meningitis lesions in rabbits dropped from 32% to 11% after two weeks of treatment, and a similar decline was observed among most human patients with TBM. The findings in Science Translational Medicine suggest that PET may be used to optimize TBM treatments and prompt the development of personalized treatments for methicillin-resistant Staphylococcus aureus and other serious infections, researchers said.
PET shows promise in assessing tuberculosis meningitis treatments
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.